The research led by Professor Kwang-Hyun Cho at KAIST represents a paradigm shift in cancer therapy. Rather than focusing on the elimination of cancer cells, this innovative approach aims to revert cancer cells to a normal-like state by systematically analyzing their gene networks and differentiation trajectories. This strategy offers a potential solution to the long-standing challenges of treatment resistance and adverse side effects associated with traditional therapies.
- Key Highlights of the Research:
1. Digital Twin of Gene Networks: The team created a computational “digital twin” of the gene network involved in the differentiation of normal colon cells. This allowed precise identification of molecular switches crucial for inducing normal cell-like behavior in cancer cells.
2. Master Molecular Switches: Through simulation analysis and experiments, the research identified critical molecular targets that, when modulated, can revert cancer cells to a state resembling healthy colon cells.
3. Proof of Concept: The effectiveness of this approach was confirmed through cellular and molecular experiments and animal studies, demonstrating the feasibility of cancer reversion therapy.
4. Broad Applicability: This systematic methodology has the potential to be applied to other cancer types, paving the way for a universal framework for reversible cancer therapies.
5. Practical Development: The findings have been transferred to BioRevert Inc., a company focused on developing practical applications of this groundbreaking therapy.
Potential Impact: • Reduced Side Effects: By avoiding the destruction of cells, this approach minimizes harm to healthy tissues, a major drawback of existing treatments like chemotherapy and radiation.
• Addressing Resistance: Cancer reversion could bypass the issue of cancer cells developing resistance, a common problem with traditional therapies.
• New Therapeutic Concept: The introduction of a “reversible cancer therapy” challenges the traditional paradigm of cancer treatment, opening new avenues for research and clinical application.
Publication and Support: The research, titled “Control of Cellular Differentiation Trajectories for Cancer Reversion,” was published in Advanced Science. It was supported by South Korea’s Ministry of Science and ICT and the National Research Foundation of Korea, demonstrating strong national backing for transformative scientific advancements.
This development holds significant promise for the future of cancer treatment, moving beyond the destructive methods of the past toward a more refined and patient-friendly approach.
